Volume 4.32 | Aug 20

Hematopoiesis News 4.32 August 20, 2013
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
 
TOP STORY
Mutant IDH1 Promotes Leukemogenesis In Vivo and Can Be Specifically Targeted in Human Acute Myeloid Leukemia
Scientists investigated the role of mutant isocitrate dehydrogenase 1 (IDH1) using the mouse transplantation assay. Mutant IDH1 alone did not transform hematopoietic cells during 5 months of observation. However, mutant IDH1 greatly accelerated onset of myeloproliferative disease-like myeloid leukemia in mice in cooperation with HoxA9 with a mean latency of 83 days compared to cells expressing HoxA9 and wildtype IDH1 or a control vector. [Blood] Abstract
Free Nature Reviews Immunology Poster: The Immune Response to HIV
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Wnt5a Regulates Hematopoietic Stem Cell Proliferation and Repopulation Through the Ryk Receptor
The authors tested the hypothesis that the Ryk protein, a Wnt ligand receptor that can bind the Wnt5a ligand, regulated the response of hematopoietic stem cells (HSCs) to Wnt5a. They observed that inhibiting Ryk blocked the ability of Wnt5a to induce HSC quiescence and enhance short-term and long-term hematopoietic repopulation. [Stem Cells] Abstract

Characteristic Phenotypes Associated with Congenital Dyserythropoietic Anemia (Type II) Manifest at Different Stages of Erythropoiesis
Scientists employed an in vitro culture system to monitor the appearance of the defining phenotypes associated with Congenital Dyserythropoietic Anemia Type II during terminal differentiation of erythroblasts derived from small volumes of patient peripheral blood. [Haematologica] Abstract | Full Article

CD137 Ligand Reverse Signaling Skews Hematopoiesis towards Myelopoiesis during Aging
CD137L is expressed on the surface of hematopoietic progenitor cells, and upon binding to CD137 induces reverse signaling into hematopoietic progenitor cells promoting their activation, proliferation and myeloid differentiation. Since aging is associated with an increasing number of myeloid cells researchers investigated the role of CD137 and CD137L on myelopoiesis during aging. [Aging] Full Article

Utilization of TREC and KREC Quantification for the Monitoring of Early T- and B-Cell Neogenesis in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation
Scientists examined whether quantification of T cell receptor excision circle, (TREC) and kappa-deleting recombination excision circle (KREC) before and within six months after allogeneic hematopoietic stem cell transplantation could be used to measure the thymic and bone marrow outputs in such patients. [J Transl Med] Full Article

CLINICAL RESEARCH

Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma
Scientists reviewed characteristics and outcomes of 20,278 patients undergoing autologous hematopoietic progenitor cell transplantation within 12 months of multiple myeloma diagnosis in the US and Canada and registered at the Center for International Blood and Marrow Transplant Research in three time cohorts: 1995-1999, 2000-2004 and 2005-2010, reflecting increasing availability of novel drugs. [Biol Blood Marrow Transplant] Abstract

Addition of Plerixafor for CD34+ Cell Mobilization in Six Healthy Stem Cell Donors Ensured Satisfactory Grafts for Transplantation
The authors present six cases in which the “just-in-time” addition of plerixafor ensured proper CD34+ collection from healthy donors with insufficient granulocyte-colony-stimulating factor mobilization. In four of these cases a high number of CD34+ cells was needed due to subsequent CD34+ selection or haploidentical transplantation. [Transfusion] Abstract

Intensive Induction Chemotherapy Followed by Myeloablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue for Young Children Newly-Diagnosed with Central Nervous System Atypical Teratoid/Rhabdoid Tumors: The Head Start III Experience
Nineteen children with newly diagnosed central nervous system atypical teratoid/rhabdoid tumor were treated on the head start III protocol. Treatment consisted of surgical resection, five cycles of induction chemotherapy, followed by consolidation with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue. [Pediatr Blood Cancer] Abstract

Register for Live Webinar: Customizing the Hematopoietic CFC Assay for Drug Development
 
SCIENCE NEWS
Chimerix Announces Top Line Data from CMX001 Phase II Adenovirus Study and Late-Breaker Presentation at ICAAC
Chimerix, Inc. announced top line data from the exploratory Phase II study of CMX001 as preemptive therapy for adenovirus (AdV) infection, the first interventional trial in AdV infection. In this trial in allogeneic hematopoietic cell transplant recipients, the 100 mg dose given twice weekly demonstrated decreased levels of AdV viremia and showed a potential benefit in reducing both progression to AdV disease and all-cause mortality, compared to subjects who received placebo or CMX001 given once weekly. [Press release from Chimerix, Inc. discussing research to be presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting, Denver] Press Release

From our sponsor:
Free human hematopoietic progenitors wallchart. Request your copy.
 
INDUSTRY NEWS
Epizyme Receives Orphan Drug Designation for EPZ-5676
Epizyme, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation for EPZ-5676. Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme’s proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation. [Epizyme, Inc.] Press Release

Stem Cell Research Lab to Open at Tehnopol
A stem cell research lab was opened at Tehnopol, a science park in Tallinn. In cooperation with the Cell Therapy Cluster, the Enterprise Estonia and EU-funded lab will be used to develop high-quality cell treatment products. [Estonian Public Broadcasting] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW World Stem Cell Summit (WSCS) 2013
December 4-6, 2013
San Diego, United States

Visit our events page to see a complete list of events in the hematopoiesis research community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Gene Expression and Regulation in Stem Cell Biology (University of Texas Medical School)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate – Stem Cell and Leukemia Epigenetics (King’s College London)

Postdoctoral Position – Hematopoietic Stem Cells (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoiesis (Lund Stem Cell Center)

Postdoctoral Research Associates – Stem Cell Biology (University of Illinois at Chicago)

Postdoctoral Fellow – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)

Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Hematopoiesis News: Archives | Events | Contact Us